India rejects Bayer Nexavar CL appeal

India's apex court recently dismissed Bayer's plea in the high profile Nexavar (sorafenib tosylate) compulsory licensing litigation, but the case hearing appears yet again to have touched upon the delicate issue of R&D spends along the way.

India's apex court recently dismissed Bayer's plea in the high profile Nexavar (sorafenib tosylate) compulsory licensing litigation, but the case hearing appears yet again to have touched upon the delicate issue of R&D spends along the way.

In its order dated 12 December, the Supreme Court of India dismissed Bayer's special leave petition, keeping ''all questions of...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Japan

More from Focus On Asia